{"id":"ziltivekimab-c","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL4297732","moleculeType":"Antibody"},"_fixedAt":"2026-03-30T11:55:42.312242","_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Ziltivekimab binds to and neutralizes circulating interleukin-6, a key pro-inflammatory cytokine implicated in atherosclerosis and cardiovascular disease. By blocking IL-6, the drug aims to reduce systemic inflammation and lower the risk of major adverse cardiovascular events in patients with established coronary artery disease or at high cardiovascular risk.","oneSentence":"Ziltivekimab is a monoclonal antibody that inhibits interleukin-6 (IL-6) signaling to reduce inflammation and cardiovascular risk.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:20.399Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reduction of cardiovascular risk in patients with coronary artery disease and elevated inflammatory markers"}]},"_fixedFields":["pubmed(17)"],"trialDetails":[{"nctId":"NCT05721989","phase":"PHASE1","title":"A Research Study Looking Into Blood Levels of Three Different Formulations of the Study Medicine Ziltivekimab","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-02-03","conditions":"Healthy Participants","enrollment":267},{"nctId":"NCT05021835","phase":"PHASE3","title":"ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2021-08-30","conditions":"Cardiovascular Risk, Chronic Kidney Disease, Inflammation","enrollment":6200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"recentPublications":[],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ziltivekimab C","genericName":"Ziltivekimab C","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ziltivekimab C is an interleukin-6 inhibitor, a type of antibody that targets interleukin-6. It is being studied in clinical trials for various conditions, including cardiovascular risk, chronic kidney disease, inflammation, and in healthy participants.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}